“conducting drug-drug and drug-gene interaction testing on patients with a high risk of adverse drug events (ADEs) could reduce the risk of death by 85 percent while producing an estimated cost savings of $4382 per capita.”

Costs saved outweigh costs incurred by PGx testing. Not to mention the quality of life benefits 🙂

Patients taking multiple medications may benefit from the combination of genetic testing and the use of clinical decision support tools, a new study suggests.

Source: Genomics, Clinical Decision Support Combo Cuts ED Visits by 42%